Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:COLL NASDAQ:IMAB NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.66-0.6%$1.74$1.41▼$5.01$9.18M1.1927,974 shs93,479 shsCOLLCollegium Pharmaceutical$31.20-3.3%$30.14$23.23▼$42.29$1.00B0.64396,663 shs219,382 shsIMABI-Mab$2.10-2.8%$1.88$0.60▼$3.08$171.49M1.4391,325 shs151,326 shsSTOKStoke Therapeutics$13.22+7.0%$10.89$5.35▼$16.15$721.81M1.14678,585 shs1.55 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+0.60%-5.65%-4.84%+11.30%-58.15%COLLCollegium Pharmaceutical+1.54%-2.24%+9.58%+19.44%+1.00%IMABI-Mab+0.47%+5.37%-12.55%+154.12%+42.11%STOKStoke Therapeutics+3.78%+2.57%+5.92%+60.60%-9.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.9391 of 5 stars3.53.00.00.02.70.81.3COLLCollegium Pharmaceutical4.4186 of 5 stars3.42.00.03.03.50.82.5IMABI-Mab2.871 of 5 stars3.73.00.00.02.41.70.6STOKStoke Therapeutics4.2364 of 5 stars3.61.00.04.83.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50833.73% UpsideCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7540.22% UpsideIMABI-Mab 3.33Buy$6.00185.71% UpsideSTOKStoke Therapeutics 3.29Buy$25.8095.16% UpsideCurrent Analyst Ratings BreakdownLatest STOK, APRE, IMAB, and COLL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025STOKStoke TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.007/9/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.007/9/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.12N/AN/A$3.55 per share0.47COLLCollegium Pharmaceutical$631.45M1.59$12.14 per share2.57$7.10 per share4.39IMABI-Mab$3.89M44.08N/AN/A$2.47 per share0.85STOKStoke Therapeutics$36.56M19.74N/AN/A$4.32 per share3.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)COLLCollegium Pharmaceutical$69.19M$1.2225.575.18N/A6.61%99.08%15.14%8/6/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.7916.73N/AN/A26.33%19.08%15.72%8/6/2025 (Estimated)Latest STOK, APRE, IMAB, and COLL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COLLCollegium Pharmaceutical$1.88N/AN/AN/A$182.26 millionN/A8/11/2025Q2 2025APREAprea Therapeutics-$0.77N/AN/AN/AN/AN/A8/6/2025Q2 2025STOKStoke Therapeutics-$0.0905N/AN/AN/A$31.51 millionN/A5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.905.90COLLCollegium Pharmaceutical3.301.081.01IMABI-MabN/A22.3522.35STOKStoke TherapeuticsN/A8.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%COLLCollegium PharmaceuticalN/AIMABI-Mab38.38%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%COLLCollegium Pharmaceutical2.51%IMABI-Mab22.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableSTOKStoke Therapeutics10054.60 million49.41 millionOptionableSTOK, APRE, IMAB, and COLL HeadlinesRecent News About These CompaniesStoke Therapeutics (NASDAQ:STOK) Shares Gap Up - What's Next?July 18 at 12:03 PM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Now Covered by Analysts at Jefferies Financial GroupJuly 18 at 9:31 AM | marketbeat.comEpilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJuly 15 at 10:23 PM | theglobeandmail.comStoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years agoJuly 15 at 10:37 AM | finance.yahoo.comThe charming Stoke-on-Trent four-bed family home that's 'ready to be lived in'July 13, 2025 | msn.comNew Royal Stoke technology cuts hospital stays by over a dayJuly 13, 2025 | msn.comStoke City Boss Delighted To Finally Get Signing Over The LineJuly 13, 2025 | therealefl.co.ukTGrit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winterJuly 13, 2025 | msn.comFive of the best beer gardens around Stoke-on-Trent to enjoy in the sunJuly 13, 2025 | msn.comMan City prospect told to gain notoriety at Stoke CityJuly 13, 2025 | msn.comCase builds for Biogen, Stoke's Dravet syndrome drugJuly 11, 2025 | pharmaphorum.comPLille rival Aston Villa in race for Stoke’s Sol SidibéJuly 10, 2025 | sports.yahoo.comAston Villa want Stoke City midfielder Sol SidibeJuly 10, 2025 | sports.yahoo.comStoke City vs Shrewsbury LIVE Score Updates: Match CanceledJuly 10, 2025 | vavel.comVCouncil still against Stoke-on-Trent 'merger' as devolution decision gets nearerJuly 10, 2025 | msn.comLive updates after 'accident' on Stoke-on-Trent roadJuly 10, 2025 | stokesentinel.co.ukSStoke City close in on fourth summer signingJuly 10, 2025 | msn.comBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10, 2025 | globenewswire.comStoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10, 2025 | businesswire.comLive updates as firefighters on scene of Stoke-on-Trent blazeJuly 8, 2025 | stokesentinel.co.ukSPolice helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent parkJuly 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseConagra at Rock Bottom: 7% Yield & Turnaround PoisedBy Thomas Hughes | July 13, 2025View Conagra at Rock Bottom: 7% Yield & Turnaround PoisedSTOK, APRE, IMAB, and COLL Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.66 -0.01 (-0.60%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.05 (+2.71%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Collegium Pharmaceutical NASDAQ:COLL$31.20 -1.06 (-3.29%) Closing price 04:00 PM EasternExtended Trading$31.20 0.00 (-0.02%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.I-Mab NASDAQ:IMAB$2.10 -0.06 (-2.78%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.00 (+0.24%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Stoke Therapeutics NASDAQ:STOK$13.22 +0.87 (+7.04%) Closing price 04:00 PM EasternExtended Trading$13.54 +0.32 (+2.46%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.